Skip to main content

Table 2 ORs and 95% CIs for the Risk of post-stroke cognitive impairment According to sST2 quartiles

From: Soluble ST2 and risk of cognitive impairment after acute ischemic stroke: a prospective observational study

  sST2, pg/mL p value for trend
< 117.60 117.60–163.51 163.51–238.77 ≥238.77
Median 89.75 139.13 196.13 349.14  
Cognitive impairment: MoCA
 Cases, n (%) 63 (40.7) 79 (51.3) 81 (51.9) 102 (66.2) < 0.001
 Model 1 1.00 1.48 (0.93–2.35) 1.56 (0.98–2.48) 2.53 (1.55–4.12) < 0.001
 Model 2 1.00 1.57 (0.96–2.55) 1.64 (1.01–2.68) 2.35 (1.40–3.93) 0.002
 Model 3 1.00 1.58 (0.97–2.56) 1.65 (1.01–2.70) 2.38 (1.42–4.00) 0.002
Cognitive impairment: MMSE
 Cases, n (%) 69 (44.5) 73 (47.4) 81 (51.9) 100 (64.9) < 0.001
 Model 1 1.00 1.04 (0.66–1.66) 1.28 (0.80–2.04) 1.93 (1.19–3.14) 0.003
 Model 2 1.00 1.09 (0.67–1.76) 1.31 (0.81–2.12) 1.76 (1.06–2.92) 0.021
 Model 3 1.00 1.10 (0.68–1.78) 1.33 (0.82–2.16) 1.82 (1.09–3.03) 0.016
  1. MoCA score of < 23 or MMSE score of < 27 indicates cognitive impairment
  2. Model 1: adjusted for age, sex, and education level;
  3. Model 2: adjusted for model 1 and further adjusted for current smoking, alcohol drinking, time from onset to randomization, systolic blood pressure, baseline National Institutes of Health Stroke Scale score, baseline modified Rankin Scale score, medical history (hypertension, diabetes mellitus, hyperlipidemia, and coronary heart disease), use of antihypertensive medications, randomized treatment, ischemic stroke subtype, anticoagulant treatment and hypoglycemic treatment
  4. Model 3: adjusted for model 2 and further adjusted for hsCRP
  5. Abbreviations: sST2 soluble suppression of tumorigenicity 2, MoCA Montreal Cognitive Assessment, MMSE Mini-Mental State Examination, OR odds ratio